NICE drafts negative assessment of Vidaza in leukaemia
This article was originally published in Scrip
Executive Summary
Patients in the national health service in England and Wales with myelodysplastic syndromes , chronic myelomonocytic leukaemia and acute myeloid leukaemia are unlikely to be treated with Celgene's Vidaza (azacitidine) after an initial negative assessment by the National Institute for health and Clinical Excellence.